Innovations in cancer diagnostics
Better understanding of the biology underlying patient tumors
bioTheranostics provides molecular diagnostic tests that improve the classification of cancer, and support physicians in determining a more specific breast cancer prognosis or individual risk of recurrence for patients.
All tests are real time, RT-PCR based assays that are compatible with readily available, formalin-fixed paraffin embedded (FFPE) needle core biopsies, excisional biopsies, and/or surgical samples.
Molecular cancer classification that identifies primary site of origin
THEROS CancerTYPE ID® is a molecular classification assay that measures and integrates the expression of 92 genes to distinguish up to 39 different tumor types and 64 subtypes.1 This test guides physicians in differential diagnoses and identification of the primary cancer site in the case of metastatic cancer.
Molecular insights that improve breast cancer risk prognosis and management
THEROS Breast Cancer IndexSM, a combination of THEROS H/ISM (HOXB13:IL17BR) and THEROS MGISM (Molecular Grade Index), refines and improves risk prognosis in patients with estrogen receptor-positive, lymph node-negative breast cancer. This test results in a more complete picture of prognostic information necessary for recurrence risk, therapeutic options such as endocrine therapy, and treatment decisions for each individual patient.
References:
1. Ma, et al. Molecular Classification of Human Cancers Using a 92-Gene Real Time Quantitative Polymerase Chain Reaction Assay. Archives of Pathology and Laboratory Medicine, 130: 465-473, 2006.
